New study underway in the US and approval from the Food and Drug Administration (FDA)

17 Mar, 2020

The meeting between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA, was held as scheduled on Friday. As previously announced, it was a formal meeting for the start-up and review of routines and equipment.

– I am very excited about the study and look forward to start patient recruitment, says James A. Eastham, Chief of the Urology Service at Memorial Sloan Kettering Cancer Center.

FDA has approved SpectraCure’s new protocol for clinical trials, enabling more patients to be treated at a faster rate, which increases the basis of analysis for further clinical trials. As previously announced, the updated software, the new, more user-friendly interface, which communicates with the dose planning platform IDOSE and controls the hardware has also been approved. The enhanced graphics mean higher resolution images and a more natural workflow for the doctors in the study. It becomes easier and faster to create a treatment plan in the system and the doctors also get better reconnection during the treatment itself.